中国·bmw11222(股份)有限公司-官方网站

About Ribo
Science
Pipeline
Collaboration
Careers
Contact Information
About Ribo
International R&D Center
Our Story
Leadership Team
Scientific Advisory Board
News
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Therapeutic Area
Pipeline
Products
Clinical Trials
BD and Collaboration
Our Culture
Career Development
Recruitment
Contact Information
CN
d3-pcbanner-33.jpg d3-phbanner.jpg
Clinical Trials
PipelineClinical Trials
Phase 1 Clinical Trial in Healthy Subjects in Australia (NCT05653037)

This was a randomized, single-blind, placebo-controlled phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses (“SAD”) of subcutaneously administered RBD4059 in healthy subjects.
Phase 2a Clinical Trial in Patients with Coronary Artery Disease in Sweden (NCT06717074)

This a randomized, double-blind, placebo-controlled phase 2a trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059 in participants with stable coronary artery disease.
Phase 1 Clinical Trial in Healthy Subjects in Australia (NCT05539651)

This was a randomized, double-blind, placebo-controlled phase 1 trial to evaluate the safety, tolerability, PK profiles and PD effect of single and multiple ascending doses (“MAD”) of subcutaneously administered RBD5044 in healthy subjects.
Phase 2 Clinical Trial in Patients with Mixed Dyslipidemia in Sweden (NCT06797401)

This is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group phase2 clinical trial to evaluate the efficacy and safety of RBD5044 subcutaneous injections in participants with mixed dyslipidemia.
Phase 1 Clinical Trial in Participants with Normal or Elevated LDL-c Cholesterol in China (NCT05912296)

This is a randomized, single blind, placebo controlled, single center phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD7022 in participants with normal or elevated LDL-c cholesterol.
Phase 1a Clinical Trial in Healthy Subjects in Australia (NCT04685564)

This was a randomized, double-blind, placebo-controlled, single dose-escalation study to observe the safety and PK of RBD1016 in healthy subjects.
Phase 1b Clinical Trial in Patients with CHB in Hong Kong (NCT05017116)

This was a randomized, double-blind, placebo-controlled, single and repeated dose escalation study to evaluate the safety, PK and preliminary pharmacodynamics (PD) of RBD1016 in patients with CHB.
Phase 2a Clinical Trial in CHD Patients in Sweden (NCT06649266)

This is a multi-center, randomized, partially blinded and placebo-controlled phase 2a study to evaluate the safety, efficacy and PK of RBD1016 in patients with CHD.
Phase 2 Global MRCT in CHB Patients (NCT05961098)

This is a multi-national, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the long-term safety and efficacy of RBD1016 on background of Nas in the treatment of CHB.
XML 地图